SAN MARINO, Calif. and MANILA, Philippines, Aug. 10 /PRNewswire/ -- Epeius Biotechnologies announced today the Bureau of Food and Drugs (BFAD), the Philippine drug regulatory body, has granted Epeius Biotechnologies accelerated approval for the company’s lead clinical product, Rexin-G for the treatment of all solid tumors. This approval closely follows the recent granting of an Expanded Access Program by BFAD to Epeius for Rexin-G, which extended Rexin-G clinical applications to patients with solid tumors, including but not limited to pancreatic cancer.
“With Rexin-G, Epeius is advancing genetic medicine worldwide. Our technology offers new treatment options for many cancer patients who are refractory to conventional chemotherapy treatment regimens,” said Erlinda Maria Gordon, M.D, Vice President of Operations and Medical Affairs of Epeius Biotechnologies. “Our preclinical and clinical data show that Rexin-G has a favorable safety profile without the serious side effects generally associated with chemotherapy.”
About Rexin-G
Rexin-G, developed by Epeius Biotechnologies, is currently in clinical trials in the U.S. for pancreatic cancer, where it has been granted orphan drug status by the FDA, and in the Philippines for all solid tumors. Rexin-G was developed to target primary and metastatic cancers, while limiting side effects within the body. Rexin-G is designed to function in the human circulatory system, and is the only targeted gene therapy product that can be effectively delivered intravenously.
About Epeius Biotechnologies
Epeius Biotechnologies applies its proprietary targeting technologies to advance the field of genetic medicine. These technologies seek out metastatic cancers to deliver a genetic payload that is highly active in a broad spectrum of chemo-resistant tumors. To learn more about Rexin-G and Epeius’ pipeline of proprietary compounds currently available for partnership, please visit us at http://www.epeiusbiotech.com.
Contact: Amy Blackley, Ph.D. Porter Novelli Life Sciences for Epeius Biotechnologies 619-849-6008 ablackley@pnlifesciences.com
Epeius Biotechnologies
CONTACT: Amy Blackley, Ph.D. of Porter Novelli Life Sciences,+1-619-849-6008, ablackley@pnlifesciences.com, for Epeius Biotechnologies
Web site: http://www.epeiusbiotech.com/
